Aggiunto il 06/12/2016

Punti Chiave

  • Differenziazione tra sindrome neurolettica maligna e infezione del SNC
  • Farmaci di controllo
  • Follow up per la sindrome neurolettica maligna
  • Gestione farmacologica della sindrome neurolettica maligna
  • Mioglobinuria
  • Scelta/cambiamento degli antipsicotici dopo un episodio di sindrome neurolettica maligna
  • Schizofrenia
  • Sindrome neurolettica maligna
  • Terapia elettroconvulsivante


1. 1. PARRY WH, MARTORANO F, COTTON EK. Management of life-threatening asthma with intravenous isoproterenol infusions. Am J Dis Child [online] 1976 Jan, 130(1):39-42 [viewed 08 June 2016] Available from: http://www.ncbi.nlm.nih.gov/pubmed/2007
2. 2. IRFAN M, CALDAS DE ALMEIDA JM, IRFAN UM, RAZA UA, FAROOQ S. Schizophrenia diagnosis and treatment by general practitioners: A cross-sectional study in district Peshawar, Pakistan. J Pak Med Assoc [online] 2015 Sep, 65(9):937 -42 [viewed 20 February 2016] Available from: http://www.ncbi.nlm.nih.gov/pubmed/26338736
3. 3. BILANAKIS N, PAPAMICHAEL G, PERITOGIANNIS V. Chemical restraint in routine clinical practice: a report from a general hospital psychiatric ward in Greece Ann Gen Psychiatry [online] 1/01/01 00:00:4 [viewed 20 February 2016] Available from: doi:10.1186/1744-859X-10-4
4. 4. ALEXANDER J.. Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting: Pragmatic randomised trial of intramuscular lorazepam v. haloperidol plus promethazine. The British Journal of Psychiatry [online] 2004 July, 185(1):63-69 [viewed 20 February 2016] Available from: doi:10.1192/bjp.185.1.63
5. 5. TSAI MC, HUANG TL. Severe neuroleptic malignant syndrome: successful treatment with high-dose lorazepam and diazepam: a case report. Chang Gung Med J [online] 2010 Sep-Oct, 33(5):576-80 [viewed 20 February 2016] Available from: http://www.ncbi.nlm.nih.gov/pubmed/20979709
6. 6. GONZáLEZ-BLANCO L, GARCíA-PRADA H, SANTAMARINA S, JIMéNEZ-TREVIñO L, BOBES J. Recurrence of neuroleptic malignant syndrome. Actas Esp Psiquiatr [online] 2013 Sep-Oct, 41(5):314-8 [viewed 20 February 2016] Available from: http://www.ncbi.nlm.nih.gov/pubmed/24096397
7. 7. PARKIN L, PAUL C, HERBISON GP. Simvastatin dose and risk of rhabdomyolysis: nested case-control study based on national health and drug dispensing data. Int J Cardiol [online] 2014 Jun 1, 174(1):83-9 [viewed 20 February 2016] Available from: doi:10.1016/j.ijcard.2014.03.150
8. 8. NAKAMURA M, IKEDA S, NAGAHARA H, HITSUMOTO T, MATSUI S, KADOTA H, SHIMIZU H, OHSHIMA K, YAKUSHIJI N, HAMADA M. A Patient with Dengue Fever Presenting with Rhabdomyolysis. Intern Med [online] 2015, 54(13):1657-60 [viewed 20 February 2016] Available from: doi:10.2169/internalmedicine.54.4094
9. 9. CHEN CY, LIN YR, ZHAO LL, YANG WC, CHANG YJ, WU KH, WU HP. Clinical spectrum of rhabdomyolysis presented to pediatric emergency department BMC Pediatr [online] 1/01/01 00:00:134 [viewed 20 February 2016] Available from: doi:10.1186/1471-2431-13-134
10. 10. BERMAN BD. Neuroleptic Malignant Syndrome: A Review for Neurohospitalists Neurohospitalist [online] 2011/01/01 00:00, 1(1):41-47 [viewed 20 February 2016] Available from: doi:10.1177/1941875210386491
11. 11. HASHIM H, ZEB-UN-NISA, ALRUKN SA, AL MADANI AA. Drug resistant neuroleptic malignant syndrome and the role of electroconvulsive therapy. J Pak Med Assoc [online] 2014 Apr, 64(4):471-3 [viewed 20 February 2016] Available from: http://www.ncbi.nlm.nih.gov/pubmed/24864649
12. 12. GUPTA S, NIHALANI ND. Neuroleptic Malignant Syndrome: A Primary Care Perspective Prim Care Companion J Clin Psychiatry [online] 2004/01/01 00:00, 6(5):191-194 [viewed 20 February 2016] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC518983